# Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

> **NCT01767155** · PHASE3 · COMPLETED · sponsor: **AEterna Zentaris** · enrollment: 511 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** AEZS-108 / zoptarelin doxorubicin
- **DRUG:** doxorubicin

## Key facts

- **NCT ID:** NCT01767155
- **Lead sponsor:** AEterna Zentaris
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2017-01-30
- **Final completion:** 2017-01-30
- **Target enrollment:** 511 (ACTUAL)
- **Last updated:** 2018-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01767155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01767155, "Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01767155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*